Literature DB >> 9753612

Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

T Akatsu1, T Murakami, M Nishikawa, K Ono, N Shinomiya, E Tsuda, S Mochizuki, K Yamaguchi, M Kinosaki, K Higashio, M Yamamoto, K Motoyoshi, N Nagata.   

Abstract

Osteoclastogenesis inhibitory factor (OCIF) was originally identified as a factor inhibiting osteoclast (OC) formation. The number of OC in rats treated with OCIF decreased, suggesting that OCIF inhibits OC formation in vivo; however, it is also possible that OCIF affects the number of OC by promoting apoptosis of OC. To address this issue, the effects of OCIF on the survival of OC were examined using well established mouse culture systems. OCIF dose-dependently inhibited OC formation in mouse marrow cultures. Addition of OCIF during day 0-3 did not alter the peak levels of OC formation on day 7 and 8. However, the addition of OCIF during day 5 and thereafter resulted in the rapid decrease of the number of OC. OCIF inhibited the survival of OC formed in mouse marrow cultures in dose- and time-dependent manners. The involvement of stromal cells in OC survival was examined using crude and stromal cell-depleted OC populations. OCIF dramatically inhibited the survival of crude OC populations rich with stromal cells. However, in stromal cell-depleted OC populations, OC spontaneously decreased in the absence of OCIF and OCIF did not enhance the decrease further at least up to 48 h. Apoptotic OC were detected in detached cell populations treated with OCIF in mouse marrow cultures and a specific inhibitor for caspase-3 rescued the death of OC. OCIF mutant lacking the death domain homologous regions inhibited OC survival, though the potency was much less than native OCIF. Taken together, OCIF inhibited not only OC recruitment but also OC survival. OCIF inhibited OC survival by interfering the interaction of stromal cells with OC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753612     DOI: 10.1006/bbrc.1998.9294

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Authors:  Nathalie Saidenberg-Kermanac'h; Natacha Bessis; Delphine Lemeiter; Marie-Christine de Vernejoul; Marie-Christophe Boissier; Martine Cohen-Solal
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

3.  Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.

Authors:  Leonid Gibiansky; Liviawati Sutjandra; Sameer Doshi; Jenny Zheng; Winnie Sohn; Mark C Peterson; Graham R Jang; Andrew T Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

4.  Bisphosphonates inhibit surface-mediated osteogenesis.

Authors:  Ethan M Lotz; Christoph H Lohmann; Barbara D Boyan; Zvi Schwartz
Journal:  J Biomed Mater Res A       Date:  2020-04-21       Impact factor: 4.396

5.  Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.

Authors:  Liviawati Sutjandra; Rachelle D Rodriguez; Sameer Doshi; Mark Ma; Mark C Peterson; Graham R Jang; Andrew T Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

6.  Serum markers of bone turnover in dialyzed patients separated according to age.

Authors:  Alicja E Grzegorzewska; Monika Młot
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

7.  sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

Authors:  K K Doumouchtsis; A I Kostakis; S K Doumouchtsis; M P Tziamalis; C Tsigris; M A Kostaki; D N Perrea
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

Review 8.  The TNF receptor superfamily: role in immune inflammation and bone formation.

Authors:  Xin Cheng; Masa Kinosaki; Ramachandran Murali; Mark I Greene
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice.

Authors:  Paloma Valverde; Jin Zhang; Amanda Fix; Ji Zhu; Wenli Ma; Qisheng Tu; Jake Chen
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

Review 10.  Applications of transgenics in studies of bone sialoprotein.

Authors:  Jin Zhang; Qisheng Tu; Jake Chen
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.